Follicular Lymphoma
Specialty Channel

Featured Article
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
True or false: Tazemetostat has demonstrated durable activity in patients with relapsed/refractory FL and mutations in EZH2.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
The _______ study established that 2 years of rituximab maintenance therapy after first-line immunochemotherapy significantly improves PFS in patients with FL.
True or False: Among patients with FL, MRD-negativity led to significantly reduced OS.
Long-term follow-up results from the PRIMA study confirm that rituximab maintenance after induction immunochemotherapy improves PFS in patients with FL.
Findings from which clinical trial suggest that obinutuzumab- and rituximab-based chemo yield similar lymphoma-related symptoms and health-related QoL improvements in treatment-naïve FL?
True or false: Tazemetostat is not FDA-approved for relapsed/refractory follicular lymphoma.
True or False: No link exists between achieving a PET-CT complete metabolic response after first line immunochemotherapy and improved survival outcomes in FL.

News

The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
Rituximab maintenance therapy significantly prolonged PFS in patients with newly diagnosed FL given R-CHOP versus rituximab plus bendamustine, according to data presented at ASH 2020.
Long-term follow-up results from the PRIMA study confirm that rituximab maintenance after induction immunochemotherapy improves PFS in patients with FL.
The FDA granted accelerated approval to tazemetostat for adult patients with confirmed EZH2-positive relapsed/refractory FL who have received at least 2 prior systemic therapies.

Interactive Features

True or false: Tazemetostat has demonstrated durable activity in patients with relapsed/refractory FL and mutations in EZH2.
The _______ study established that 2 years of rituximab maintenance therapy after first-line immunochemotherapy significantly improves PFS in patients with FL.
True or False: Among patients with FL, MRD-negativity led to significantly reduced OS.
Findings from which clinical trial suggest that obinutuzumab- and rituximab-based chemo yield similar lymphoma-related symptoms and health-related QoL improvements in treatment-naïve FL?
Stay in the know.
OncNet Newsletter